Nivalis Therapeutics Inc Stock Nasdaq
Equities
US65481J1097
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 17.7M | Sales 2025 * | 20.32M | Capitalization | 4.46B |
---|---|---|---|---|---|
Net income 2024 * | -97M | Net income 2025 * | -115M | EV / Sales 2024 * | 231 x |
Net cash position 2024 * | 376M | Net cash position 2025 * | 302M | EV / Sales 2025 * | 204 x |
P/E ratio 2024 * |
-48.1
x | P/E ratio 2025 * |
-36.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.04% |
Latest transcript on Nivalis Therapeutics Inc
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |